DESIGN THERAPEUTICS
Design Therapeutics is a biotechnology company developing a new class of therapies for serious degenerative disorders caused by nucleotide repeat expansions. The company’s lead program is focused on the treatment of Friedreich’s ataxia and discovery efforts are ongoing in other degenerative diseases.
DESIGN THERAPEUTICS
Social Links:
Industry:
Biotechnology Life Science Medical
Founded:
2017-01-01
Address:
Solana Beach, California, United States
Country:
United States
Website Url:
http://www.designtx.com
Total Employee:
1+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
170.73 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Content Delivery Network Google Universal Analytics Global Site Tag Nginx
Similar Organizations
Affinia Therapeutics
Affinia Therapeutics is a biotechnology company developing transformative AAV gene therapies for people with devastating diseases.
Atalanta Therapeutics
Atalanta Therapeutics is a biotechnology company pioneering new treatment options for neurodegenerative diseases.
Electra Therapeutics
Electra Therapeutics is a clinical stage biotechnology company developing therapies for cancer and other immunological diseases.
Seismic Therapeutic
Seismic Therapeutic is a biotechnology company advancing machine learning for immunology drug development.
Vigil Neuroscience
Vigil Neuroscience is a biotechnology company that develops novel therapeutics for neurodegenerative diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Quan Capital
Quan Capital investment in Series B - Design Therapeutics
Janus Henderson Investors
Janus Henderson Investors investment in Series B - Design Therapeutics
Wellington Management
Wellington Management investment in Series B - Design Therapeutics
BlackRock
BlackRock investment in Series B - Design Therapeutics
Logos Capital
Logos Capital investment in Series B - Design Therapeutics
Vivo Capital
Vivo Capital investment in Series B - Design Therapeutics
T. Rowe Price
T. Rowe Price investment in Series B - Design Therapeutics
RA Capital Management
RA Capital Management investment in Series B - Design Therapeutics
Surveyor Capital
Surveyor Capital investment in Series B - Design Therapeutics
WestRiver Group
WestRiver Group investment in Series B - Design Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2022-02-01 | Design Therapeutics Appoints Drug Development Expert, Jae Kim, M.D., as Chief Medical Officer |
Official Site Inspections
http://www.designtx.com Semrush global rank: 6.92 M Semrush visits lastest month: 695
- Host name: 83.162.211.130.bc.googleusercontent.com
- IP address: 130.211.162.83
- Location: Mountain View United States
- Latitude: 37.4043
- Longitude: -122.0748
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94043
More informations about "Design Therapeutics"
Design Therapeutics – Designing a New Class of …
A New Approach to Treating Genetic Disease. We are a biopharmaceutical company advancing novel, small molecule therapeutic candidates designed to bring functional cures to serious genetic diseases with long-standing unmet …See details»
Design Therapeutics - LinkedIn
Design Therapeutics | 2,333 followers on LinkedIn. We are a clinical-stage biotechnology company developing a new class of therapies based on its platform of GeneTAC™ gene …See details»
Our Programs – Design Therapeutics
We are developing a portfolio of GeneTAC ® product candidates designed to address genetic diseases driven by inherited nucleotide repeat expansions. GeneTAC ® molecules are …See details»
News Release Details - investors.designtx.com
Mar 10, 2025 Discovery efforts are underway for multiple genomic medicines. For more information, please visit designtx.com. Forward-Looking Statements Statements in this press …See details»
Design Therapeutics, Inc. - Drug pipelines, Patents, Clinical trials ...
Jan 23, 2025 For more information, please visit designtx.com. Contact:Renee LeckTHRUST Strategic [email protected] . Gene Therapy. ... The statistics for drugs in …See details»
Design Therapeutics - Overview, News & Similar companies
Dec 11, 2024 www.designtx.com. Revenue $63.4 Million. Stock Symbol DSGN. Industry Business Services General Business Services . Most Recent Scoops. Dec 12 2024. Project. …See details»
Design Therapeutics - Crunchbase Company Profile & Funding
Contact Email [email protected] Design Therapeutics is a biotechnology company developing a new class of therapies for serious degenerative disorders caused by nucleotide repeat …See details»
Investors & Media | Design Therapeutics, Inc
3 days ago The Investor Relations website contains information about Design Therapeutics, Inc's business for stockholders, potential investors, and financial analysts.See details»
Design Therapeutics Company Overview, Contact Details
Jan 27, 2021 For more information, please visit designtx.com. Sign up for free to view info. Email Format Employee directory . Company Overview. Headquarters Carlsbad, CA 92011 US. …See details»
Designtex - Leadership Team - The Org
The Leadership Team at Designtex drives the company's strategic vision, overseeing operations, research and development, marketing, and sales initiatives.See details»
Design Therapeutics Inc. - Cruelty Free Investing
Design Therapeutics Inc is a biopharmaceutical company. The Company is focused on developing disease-modifying small-molecule therapeutic candidates, called gene targeted …See details»
Contact IR | Design Therapeutics, Inc - investors.designtx.com
Design Therapeutics. 6005 Hidden Valley Road Suite 110 Carlsbad, CA 92011 858-293-4900See details»
Designtex Appoints New President - officeinsight
Apr 2, 2024 Designtex is excited to announce that Kim Land has been named President effective March 4, 2024. As a skilled strategic thinker and collaborative leader with 20+ years …See details»
Design Therapeutics to Participate in Goldman Sachs 42nd Annual …
The live webcast will be available in the investor section of the company's website at www.designtx.com. The webcast will be archived for 60 days following the presentation. About …See details»
DT-216 - Drug Targets, Indications, Patents - Synapse - Patsnap
Mar 20, 2025 Originator Organization. Design Therapeutics, Inc. Active Organization. Design Therapeutics, Inc. Inactive Organization-Drug Highest Phase Phase 1/2. ... webcasts of the …See details»
Julie Burgess, C.P.A. – Design Therapeutics
Julie Burgess is the chief accounting officer at Design Therapeutics. Ms. Burgess brings more than 25 years of experience in financial reporting, technical accounting, debt and equity …See details»
UX And Design Files Organization Template - Smashing Magazine
6 days ago Organization Starter Kit (Free Template) A while back, I stumbled upon a neat organizational starter kit by Courtney Pester. It’s an incredibly thorough setup template to get …See details»
News Releases - Design Therapeutics, Inc
3 days ago Phase 2 biomarker trial in FECD patients anticipated to begin in the second half of 2025 CARLSBAD, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. …See details»
Our Approach – Design Therapeutics
The structures of GeneTAC ® molecules enable them to bind and act specifically at the site of the disease-causing nucleotide repeat expansion. They target the mutant gene and modulate the …See details»
Deepa Prasad – Design Therapeutics
Deepa Prasad is the Executive Director of the Robinson Life Sciences Business and Entrepreneurship Program at University of California, Berkeley.See details»